|
1
|
Li TT, Alemayehu M, Aziziyeh AI, et al:
Beta-arrestin/Ral signaling regulates lysophosphatidic
acid-mediated migration and invasion of human breast tumor cells.
Mol Cancer Res. 7:1064–1077. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Barlogie B, Kyle RA, Anderson KC, et al:
Standard chemotherapy compared with high-dose chemoradiotherapy for
multiple myeloma: final results of phase III US Intergroup Trial
S9321. J Clin Oncol. 24:929–936. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Richardson P and Anderson K: Thalidomide
and dexamethasone: a new standard of care for initial therapy in
multiple myeloma. J Clin Oncol. 24:334–336. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Richardson PG, Blood E, Mitsiades CS, et
al: A randomized phase 2 study of lenalidomide therapy for patients
with relapsed or relapsed and refractory multiple myeloma. Blood.
108:3458–3464. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Brown MD and Sacks DB: IQGAP1 in cellular
signaling: bridging the GAP. Trends Cell Biol. 16:242–249. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jeong HW, Li Z, Brown MD and Sacks DB:
IQGAP1 binds Rap1 and modulates its activity. J Biol Chem.
282:20752–20762. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Roy M, Li Z and Sacks DB: IQGAP1 binds
ERK2 and modulates its activity. J Biol Chem. 279:17329–17337.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Roy M, Li Z and Sacks DB: IQGAP1 is a
scaffold for mitogen-activated protein kinase signaling. Mol Cell
Biol. 25:9740–9752. 2005.
|
|
9
|
Ren JG, Li Z and Sacks DB: IQGAP1
modulates activation of B-Raf. Proc Natl Acad Sci USA.
104:10465–10469. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sugimoto N, Imoto I, Fukuda Y, Kurihara N,
Kuroda S, Tanigami A, Kaibuchi K, Kamiyama R and Inazawa J: IQGAP1,
a negative regulator of cell-cell adhesion, is upregulated by gene
amplification at 15q26 in gastric cancer cell lines HSC39 and 40A.
J Hum Genet. 46:21–25. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sun W, Zhang K, Zhang X, Lei W, Xiao T, Ma
J, Guo S, Shao S, Zhang H, Liu Y, Yuan J, Hu Z, Ma Y, Feng X, Hu S,
Zhou J, Cheng S and Gao Y: Identification of differentially
expressed genes in human lung squamous cell carcinoma using
suppression subtractive hybridization. Cancer Lett. 212:83–93.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bertucci F, Salas S, Eysteries S, Nasser
V, Finetti P, Ginestier C, Charafe-Jauffret E, Loriod B, Bachelart
L, Montfort J, Victorero G, Viret F, Ollendorff V, Fert V,
Giovaninni M, Delpero JR, Nguyen C, Viens P, Monges G, Birnbaum D
and Houlgatte R: Gene expression profiling of colon cancer by DNA
microarrays and correlation with histoclinical parameters.
Oncogene. 23:1377–1391. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jameson KL, Mazur PK, Zehnder AM, et al:
IQGAP1 scaffold-kinase interaction blockade selectively targets
RAS-MAP kinase-driven tumors. Nat Med. 19:626–630. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Clark EA, Golub TR, Lander ES and Hynes
RO: Genomic analysis of metastasis reveals an essential role for
RhoC. Nature. 406:532–535. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nabeshima K, Shimao Y, Inoue T and Koono
M: Immunohistochemical analysis of IQGAP1 expression in human
colorectal carcinomas: its overexpression in carcinomas and
association with invasion fronts. Cancer Lett. 176:101–109. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Miyoshi T, Shirakusa T, Ishikawa Y,
Iwasaki A, Shiraishi T, Makimoto Y, Iwasaki H and Nabeshima K:
Possible mechanism of metastasis in lung adenocarcinomas with a
micropapillary pattern. Pathol Int. 55:419–424. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dong P, Nabeshima K, Nishimura N, Kawakami
T, Hachisuga T, Kawarabayashi T and Iwasaki H: Overexpression and
diffuse expression pattern of IQGAP1 at invasion fronts are
independent prognostic parameters in ovarian carcinomas. Cancer
Lett. 243:120–127. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Balenci L, Clarke ID, Dirks PB, Assard N,
Ducray F, Jouvet A, Belin MF, Honnorat J and Baudier J: IQGAP1
protein specifies amplifying cancer cells in glioblastoma
multiforme. Cancer Res. 66:9074–9082. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
White CD, Brown MD and Sacks DB: IQGAPs in
cancer: a family of scaffold proteins underlying tumorigenesis.
FEBS Lett. 583:1817–1824. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Scholl FA: MEK1/2 MAPK kinases are
essential for mammalian development, homeostasis, and Raf-induced
hyperplasia. Dev Cell. 12:615–629. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dumesic PA, Scholl FA, Barragan DI and
Khavari PA: ERK1/2 MAP kinases are required for epidermal G2/M
progression. J Cell Biol. 185:409–422. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
McCormick F: Cancer therapy based on
oncogene addiction. J Surg Oncol. 103:464–467. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nazarian R, Shi H, Wang Q, et al:
Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or
N-RAS upregulation. Nature. 468:973–977. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Johannessen CM, Boehm JS, Kim SY, et al:
COT drives resistance to RAF inhibition through MAP kinase pathway
reactivation. Nature. 468:968–972. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nikolaev SI, Rimoldi D, Iseli C, et al:
Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2
mutations in melanoma. Nat Genet. 44:133–139. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wagle N, Emery C, Berger MF, et al:
Dissecting therapeutic resistance to RAF inhibition in melanoma by
tumor genomic profiling. J Clin Oncol. 29:3085–3096. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Johnson M, Sharma M and Henderson BR:
IQGAP1 regulation and roles in cancer. Cell Signal. 21:1471–1478.
2009. View Article : Google Scholar
|
|
28
|
White CD, Erdemir HH and Sacks DB: IQGAP1
and its binding proteins control diverse biological functions. Cell
Signal. 24:826–834. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jadeski L, Mataraza JM, Jeong HW, et al:
IQGAP1 stimulates proliferation and enhances tumorigenesis of human
breast epithelial cells. J Biol Chem. 283:1008–1017. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu Z, Liu D, Bojdani E, et al: IQGAP1
plays an important role in the invasiveness of thyroid cancer. Clin
Cancer Res. 16:6009–6018. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sato A, Naito T, Hiramoto A, et al:
Association of RNase L with a RAS GTPase-activating-like protein
IQGAP1 in mediating the apoptosis of a human cancer cell-line. FEBS
J. 277:4464–4473. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li S, Wang Q, Chakladar A, et al: Gastric
hyperplasia in mice lacking the putative Cdc42 effector IQGAP1. Mol
Cell Biol. 20:697–701. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kawano M, Hirano T, Matsuda T, et al:
Autocrine generation and requirement of BSF-2/IL-6 for human
multiple myelomas. Nature. 332:83–85. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pene F, Claessens Ye, Muller O, et al:
Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase
pathways in the proliferation and apoptosis in multiple myeloma.
Oncogene. 21:6587–6597. 2002. View Article : Google Scholar : PubMed/NCBI
|
